Navigation Links
Profectus BioSciences Inc. Names Shawn Patrick O'Brien CEO
Date:1/28/2008

New leadership brings biotech and large pharma experience to lead

commercialization phase for a leading AIDS/HIV R&D company

BALTIMORE, Jan. 28 /PRNewswire/ -- Profectus BioSciences Inc., a biotechnology company that develops preventative and therapeutic technologies to reduce the morbidity and mortality of viral diseases, today announced that its board of directors has appointed Shawn Patrick O'Brien as the company's president and chief executive officer. O'Brien will also serve as a director of the company. The appointment comes as Profectus BioSciences enters the commercialization phase of operations.

To date, Profectus BioSciences has a unique relationship with the Institute of Human Virology (http://www.IHV.org), along with other academic and government institutions to gain access to breakthrough technologies focused on the treatment and prevention of AIDS/HIV. Currently, the Company has five technology platforms and two commercialization partners to progress the development of its AIDS vaccine for human and veterinary use. The Company plans to work with other commercialization partners to progress the other four promising technology platforms in the treatment of AIDS/HIV.

O'Brien has extensive global experience in business development, sales, licensing, and R&D at biotech and large pharma companies. He comes to Profectus BioSciences from Solstice Neurosciences Inc., where he served as president and chief executive officer since 2004. During his tenure at Solstice, O'Brien increased key sales by 90 percent, opened the EU market with new partners and patents, addressed unsettled patent issues and expanded the clinical development program to include six investigational new drugs (INDs).

Previously, O'Brien worked with AstraZeneca USA as vice president of commercial operations for emerging brands, and as vice president and therapy area leader for the respiratory and infla
'/>"/>

SOURCE Profectus BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  Cellular Biomedicine Group (OTCQB: CBMG) today ... the total projected enrollment required for its Phase ... efficacy of the medical technology haMPC (Human Adipose-derived ... To date the trial has had no Severe ... I open label clinical research trial for KOA, ...
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- Aridis ... been reached with Switzerland -based ... anti-infective human monoclonal antibody (mAb) products, and technologies. ... mAb products for treatment of infections by common ... Staphylococcus aureus , Pseudomonas aeruginosa , ...
(Date:5/17/2013)... Men’s skin is biologically different than women’s skin,( says ... been known to react more aggressively when hormones change, and ... puberty, other acne causing factors like P.acnes bacteria and excess ... with unsightly acne scars. Adult acne treatment, Probiotic Action shares ... how to reduce and prevent acne scarring. , In order ...
(Date:5/17/2013)... RURO Inc. is pleased to announce ... refinement to the smart management solution. , ezColony, ... methodical management for transgenic animal colonies, genotyping and ... platform provides user access with a plethora of ... emphasize streamlined tasks, such as animal relocation to ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2
... Celsion Corporation (Nasdaq: CLSN ), an oncology ... of innovative oncology drugs, today announced that it has ... select group of institutional investors, including certain officers and ... 8% redeemable convertible preferred stock with a stated value ...
... massive death of brain cells after a stroke, the explosion in ... as autism, schizophrenia and mental retardation show no physical signs of ... brain cells communicate with one another. To understand ... activity is key. But even the best imaging devices available ...
... success of the previous conferences of the series held ... (EPD) conferences are a leading venue for experts from ... as a processing technique for fabrication of both traditional ... electric surface charge on particles in suspension, which migrate ...
Cached Biology Technology:Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million 2Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million 3Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million 4New UCLA-designed microscope records firing of thousands of individual neurons in 3-D 2New UCLA-designed microscope records firing of thousands of individual neurons in 3-D 34th International Conference on Electrophoretic Deposition 24th International Conference on Electrophoretic Deposition 34th International Conference on Electrophoretic Deposition 4
(Date:5/17/2013)... of proteins in the brain responsible for protecting nerve ... could increase cell survival. , The discovery, made by ... in the EMBO journal with additional comment ... for stroke and other brain diseases. , The research ... a protein, known as SUMO, responsible for controlling the ...
(Date:5/17/2013)... of American Societies for Experimental Biology (FASEB) released a ... (NIH) funding trends highlighting the devastating impact of sequestration ... FASEB analysis follows a May 15th Senate Appropriations Committee ... testified that the $1.6 billion cut the agency sustained ... substantial impact on the scientific community." , According ...
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) Program ... Society for Developmental Biology (SDB) 72nd Annual Meeting ... awards are meant to promote the entry of ... the mainstream of the basic science community and ... the SDB 2013 Annual Meeting. , Awards are ...
Breaking Biology News(10 mins):SUMO wrestling cells reveal new protective mechanism target for stroke 2
... China - A group of scientists from United Kingdom (UK), ... sequencing of peregrine and saker falcons genomes at the 2nd ... study is a part of Falcon Genome Project, launched and ... this January. The results will enable biologists to better study ...
... BioInnovation Institute in Akron (ABIA) and the U.S. Food ... collaboration to support and develop regulatory science for the ... Effective today, the FDA and ABIA executed a ... draw upon ABIA resourcesincluding a library of test methods ...
... -- Believed critical for determining which individuals can -- or ... figure prominently in the origin of new species, but are ... new species form. Today, new international research led ... the exact shape and fit of genitalia steals the show ...
Cached Biology News:Genomic sequences of 2 iconic falconry birds - Peregrine and Saker Falcons- successfully decoded 2FDA, ABIA to collaborate on safety and performance of materials used in medical devices 2Shape, fit of reproductive organs evolve quickly and in concert, leaving size behind 2Shape, fit of reproductive organs evolve quickly and in concert, leaving size behind 3
Troponin I Immunogen: Full length native protein (purified) (Human). Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-SDF-1β/PBSF affinity isolated antibody lyophilized powder Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline recombinant human SDF-1β/PBSF expressed in E....
Immulon 4 HBX 1x12 Strip, flat bottom; high binding extra surface with special resin and irradiation, offers maximum protein uptake....
...
Biology Products: